Clinical trials
Locally Advanced Rectal Carcinoma clinical trials
Below are recruiting locally advanced rectal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 73 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06312982RecruitingPhase 2/Phase 3
Chemo, radiation, and immunotherapy before rectal cancer surgery
This trial tests whether a combination of chemotherapy, radiation, and an immunotherapy drug (tislelizumab) before surgery can improve outcomes for people with locally advanced rectal cancer that has specific protein/gene markers (pMMR or MSS). It’s designed for those who have not yet had any treatment for their cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06653452Recruiting
PET/MRI for rectal cancer treatment response
This study uses a special scan called PET/MRI to see how well treatment works for locally advanced rectal cancer before surgery. It may help doctors choose the best treatment plan for you.
Beijing, Beijing MunicipalityAges 18–75 - NCT06762405RecruitingPhase 3
Testing dostarlimab with short radiation for MSI rectal cancer
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
DijonAges 18 years+ - NCT06765616RecruitingPhase 2
Immunotherapy with chemo and radiation for rectal cancer before surgery
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Jinan, ShandongAges 18–85 - NCT06770270RecruitingPhase 2
Immunotherapy with radiation and chemo before rectal cancer surgery
This trial tests adding an immunotherapy drug (pucotenlimab) to standard radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT06787183RecruitingPhase 2
Short-course radiation with chemoimmunotherapy for rectal cancer that has spread to the liver
This trial tests whether combining short-course radiation with a chemotherapy regimen (CAPOX) and an immunotherapy drug (QL1706) can help treat rectal cancer that has spread to the liver. It is designed for patients who have not had any prior cancer treatment.
Fuzhou, FujianAges 18–75 - NCT06802666RecruitingPhase 2
Short radiation plus combo drugs for rectal cancer
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
HubeiAges 18–75 - NCT06843434RecruitingPhase 2
Study of two immunotherapy drugs for rectal cancer
This trial tests a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with newly diagnosed rectal adenocarcinoma that has not spread. The goal is to see if this treatment can shrink the tumor before surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT06894797Recruiting
Chemo and radiation before and after surgery for rectal cancer
This study tests a sequence of chemotherapy and radiation before and after surgery for rectal cancer. It compares giving more chemo between the end of radiation and surgery (consolidation) versus giving some chemo before radiation starts (induction). The goal is to see which order works better.
BeijingAges 18–75 - NCT06940388RecruitingPhase 2
Immunotherapy plus standard treatment for rectal cancer
This trial is testing whether adding the immunotherapy drug tislelizumab to standard total neoadjuvant treatment (chemotherapy and radiation before surgery) can improve outcomes for people with locally advanced rectal cancer. The goal is to see if the combination helps shrink the tumor more than standard treatment alone.
MainzAges 18 years+ - NCT07005570RecruitingPhase 2
Short radiation and chemo with or without immunotherapy for rectal cancer
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) and a targeted therapy (bevacizumab) to short-course radiation followed by chemo can improve outcomes for patients with locally advanced rectal cancer that is pMMR/MSS. The goal is to shrink the tumor before surgery and possibly avoid the need for more extensive treatment.
Guangzhou, GuangdongAges 18–75 - NCT07040098RecruitingPhase 2
Optimizing immunotherapy with chemo-radiation for rectal cancer
This trial tests combining immunotherapy with standard chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to see if this approach can improve outcomes for patients whose tumors have certain genetic features (pMMR or MSS).
BeijingAges 18–75 - NCT07281157RecruitingPhase 2
Liposomal irinotecan, capecitabine and enlonstobart with short radiation for rectal cancer
This trial tests a combination of short-course radiation, two chemotherapy drugs (liposomal irinotecan and capecitabine), and an immunotherapy drug (Enlonstobart) for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor before surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07359989Recruiting
Leucine plus chemoradiation before surgery for rectal cancer
This trial tests whether adding leucine (a simple amino acid) to standard chemoradiation before surgery can help shrink rectal cancer and improve outcomes. It is for people with locally advanced rectal cancer that hasn't yet spread to other organs.
Hangzhou, ZhejiangAges 18–80 - NCT07372300RecruitingPhase 3
Heat therapy plus standard care for advanced rectal cancer
This trial tests whether adding modulated electro-hyperthermia (a gentle heat treatment) to standard therapy (radiation and chemotherapy) before surgery helps control locally advanced rectal cancer. It is for people whose cancer has not spread to other parts of the body.
Chiayi City, Dalin TownshipAges 20 years+ - NCT07393048Recruiting
Personalized ctDNA test to predict rectal cancer treatment response
This trial uses a personalized blood test (ctDNA-MRD) to see how well neoadjuvant therapy works for rectal cancer. If you have stage II or III rectal cancer that can be surgically removed, this study might help guide your treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT07511413Recruiting
Monitoring health in head, neck, lung & rectal cancer
This trial is studying how a monitoring method (bioimpedance) works for people with head and neck, lung, or rectal cancer who are about to start standard treatment. It may help doctors track your health better during therapy.
Candiolo, Torino (TO)Ages 18 years+ - NCT07514754Recruiting
Immunonutrition support during cancer treatment
This study tests whether special nutritional support (called immunonutrition) helps patients with head and neck, lung, or rectal cancer who are receiving chemotherapy, radiation, or immunotherapy. The goal is to see if it improves how well treatment works and how you feel during and after cancer care.
Candiolo, Torino (TO)Ages 18 years+ - NCT07527026RecruitingPhase 2
Camrelizumab and chemotherapy with radiation for advanced rectal cancer
This trial tests a combination of an immunotherapy drug (camrelizumab) with chemotherapy and radiation to shrink advanced rectal cancer before surgery. The goal is to help more patients have successful surgery with complete tumor removal.
Beijing, Beijing MunicipalityAges 18–75 - NCT07528209RecruitingPhase 3
Chemotherapy with or without immunotherapy for advanced rectal cancer
This study tests whether adding an immunotherapy drug (pucotenlimab) to standard chemotherapy (CAPOX) before surgery helps treat locally advanced rectal cancer better. The goal is to shrink tumors and improve survival while preserving bowel function when possible.
Guangzhou, GuangdongAges 18–75 - NCT07669220RecruitingPhase 2
Short radiation, immunotherapy, and chemo for advanced rectal cancer
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
GuangzhouAges 18–75 - NCT05663775RecruitingPhase 2
Mesalamine to prevent bowel inflammation after melanoma immunotherapy
This study tests whether taking mesalamine can prevent colitis (bowel inflammation) in people with advanced melanoma who are treated with ipilimumab plus nivolumab. It may help reduce dangerous stomach or bowel side effects from this cancer treatment.
Edmonton, AlbertaAges 18 years+ - NCT07026422RecruitingPhase 2
Combination immunotherapy with chemoradiation for high-risk rectal cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy and radiation before surgery for people with a specific type of high-risk rectal cancer. The goal is to see if adding these drugs can improve treatment results.
Jinan, ShandongAges 18–75 - NCT06028724Recruiting
Looking for cancer mutations using a blood test
This study uses a blood test (liquid biopsy) to find genetic changes in advanced solid tumors. It may help doctors choose the right treatment and monitor how well it works over time.
Aviano, PordononeAges 18 years+
Hear when a new Locally Advanced Rectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced rectal carcinoma?
- Yes. Clin2 currently lists 73 recruiting locally advanced rectal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced rectal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced rectal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Rectal Cancer
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Locally Advanced Nasopharyngeal Carcinoma
- Locally Advanced Cervical Carcinoma
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Locally Advanced Hepatocellular Carcinoma
- Locally Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced Urothelial Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.